Beam Therapeutics Q2 net loss widens more than expected

Reuters

Yesterday

Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> <a href="https://laohu8.com/S/QTWO">Q2</a> net loss widens more than expected

Overview

Beam Q2 net loss of $102.3 mln misses analyst expectations, per LSEG data
Operating income for Q2 misses estimates, pretax profit beats, per LSEG data
Beam ends Q2 with $1.2 bln cash, supporting operations into 2028

Outlook

Beam expects BEAM-302 trial data in early 2026
Company plans to present BEACON trial data by end of 2025
Beam plans Phase 1 trial for BEAM-103 by end of 2025
Company expects cash reserves to support operations into 2028

Result Drivers

COSTS - R&D costs increase but General & Administrative (G&A) expenses decline

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 License and Collaboration Revenue		$8.47 mln
Q2 Net Income	Miss	-$102.29 mln	-$95.40 mln (11 Analysts)
Q2 Operating Income	Miss	-$120.15 mln	-$104.80 mln (11 Analysts)
Q2 Pretax Profit	Beat	-$102.29 mln	-$104.90 mln (10 Analysts)
Q2 Operating Expenses		$128.62 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Beam Therapeutics Inc is $41.00, about 53.4% above its August 4 closing price of $19.12

Press Release: ID:nGNX8DNrVk

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2557395203"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2557395203\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2557395203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-05 19:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2557395203","market":"fut","top_or_hot":-1,"title":"Beam Therapeutics Q2 net loss widens more than expected","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens more than expected</title></head><body><p><span>Overview</span></p><ul><li><p>Beam Q2 net loss of $102.3 mln misses analyst expectations, per LSEG data</p></li><li><p>Operating income for Q2 misses estimates, pretax profit beats, per LSEG data</p></li><li><p>Beam ends Q2 with $1.2 bln cash, supporting operations into 2028</p></li></ul><p><span>Outlook</span></p><ul><li><p>Beam expects BEAM-302 trial data in early 2026</p></li><li><p>Company plans to present BEACON trial data by end of 2025</p></li><li><p>Beam plans Phase 1 trial for BEAM-103 by end of 2025</p></li><li><p>Company expects cash reserves to support operations into 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COSTS - R&amp;D costs increase but General &amp; Administrative (G&amp;A) expenses decline</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 License and Collaboration Revenue</p></td><td></td><td><p>$8.47 mln</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Miss</p></td><td><p>-$102.29 mln</p></td><td><p>-$95.40 mln (11 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Miss</p></td><td><p>-$120.15 mln</p></td><td><p>-$104.80 mln (11 Analysts)</p></td></tr><tr><td><p>Q2 Pretax Profit</p></td><td><p>Beat</p></td><td><p>-$102.29 mln</p></td><td><p>-$104.90 mln (10 Analysts)</p></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$128.62 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Beam Therapeutics Inc is $41.00, about 53.4% above its August 4 closing price of $19.12</p></li></ul><p>Press Release: <span>ID:nGNX8DNrVk</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beam Therapeutics Q2 net loss widens more than expected</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeam Therapeutics Q2 net loss widens more than expected\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-05 19:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens more than expected</title></head><body><p><span>Overview</span></p><ul><li><p>Beam Q2 net loss of $102.3 mln misses analyst expectations, per LSEG data</p></li><li><p>Operating income for Q2 misses estimates, pretax profit beats, per LSEG data</p></li><li><p>Beam ends Q2 with $1.2 bln cash, supporting operations into 2028</p></li></ul><p><span>Outlook</span></p><ul><li><p>Beam expects BEAM-302 trial data in early 2026</p></li><li><p>Company plans to present BEACON trial data by end of 2025</p></li><li><p>Beam plans Phase 1 trial for BEAM-103 by end of 2025</p></li><li><p>Company expects cash reserves to support operations into 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>COSTS - R&amp;D costs increase but General &amp; Administrative (G&amp;A) expenses decline</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 License and Collaboration Revenue</p></td><td></td><td><p>$8.47 mln</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td><p>Miss</p></td><td><p>-$102.29 mln</p></td><td><p>-$95.40 mln (11 Analysts)</p></td></tr><tr><td><p>Q2 Operating Income</p></td><td><p>Miss</p></td><td><p>-$120.15 mln</p></td><td><p>-$104.80 mln (11 Analysts)</p></td></tr><tr><td><p>Q2 Pretax Profit</p></td><td><p>Beat</p></td><td><p>-$102.29 mln</p></td><td><p>-$104.90 mln (10 Analysts)</p></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$128.62 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Beam Therapeutics Inc is $41.00, about 53.4% above its August 4 closing price of $19.12</p></li></ul><p>Press Release: <span>ID:nGNX8DNrVk</span></p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BEAM","symbol_name":"Beam Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nPLX262D66:1","article_id":"2557395203","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2557395203","pubTimestamp":1754392910,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Beam Therapeutics Q2 net loss widens more than expectedOverviewBeam Q2 net loss of $102.3 mln misses analyst expectations, per LSEG dataOperating income for Q2 misses estimates, pretax profit beats, p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BEAM":"Beam Therapeutics, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4556":"基因编辑","BK4139":"生物科技","BK4535":"淡马锡持仓","BK4611":"AI医疗"},"translate_title":"Beam Therapeutics第二季度净亏损扩大超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":0.9},"content_text":"Beam Therapeutics Q2 net loss widens more than expectedOverviewBeam Q2 net loss of $102.3 mln misses analyst expectations, per LSEG dataOperating income for Q2 misses estimates, pretax profit beats, per LSEG dataBeam ends Q2 with $1.2 bln cash, supporting operations into 2028OutlookBeam expects BEAM-302 trial data in early 2026Company plans to present BEACON trial data by end of 2025Beam plans Phase 1 trial for BEAM-103 by end of 2025Company expects cash reserves to support operations into 2028Result DriversCOSTS - R&D costs increase but General & Administrative (G&A) expenses declineKey DetailsMetricBeat/MissActualConsensus EstimateQ2 License and Collaboration Revenue$8.47 mlnQ2 Net IncomeMiss-$102.29 mln-$95.40 mln (11 Analysts)Q2 Operating IncomeMiss-$120.15 mln-$104.80 mln (11 Analysts)Q2 Pretax ProfitBeat-$102.29 mln-$104.90 mln (10 Analysts)Q2 Operating Expenses$128.62 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 14 \"strong buy\" or \"buy\", 3 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Beam Therapeutics Inc is $41.00, about 53.4% above its August 4 closing price of $19.12Press Release: ID:nGNX8DNrVk(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}